Qurient Co., Ltd. (KOSDAQ:115180)
South Korea · Delayed Price · Currency is KRW 26,050
+800 (3.17%)
At close: Aug 20, 2026
Qurient Revenue
Qurient had revenue of 1.94B KRW in the quarter ending March 31, 2026, with 1.12% growth. This brings the company's revenue in the last twelve months to 7.00B, down -22.07% year-over-year. In the year 2025, Qurient had annual revenue of 6.98B, down -23.94%.
Revenue (ttm)
7.00B
Revenue Growth
-22.07%
P/S Ratio
151.24
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.06T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.98B | -2.20B | -23.94% |
| Dec 31, 2024 | 9.18B | 148.03M | 1.64% |
| Dec 31, 2023 | 9.03B | 563.25M | 6.65% |
| Dec 31, 2022 | 8.47B | 3.58B | 73.33% |
| Dec 31, 2021 | 4.89B | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| HansBiomed | 124.81B |
| Aimed Bio | 66.79B |
| ROKIT Healthcare | 30.61B |
| JS Link | 20.31B |
| S.Biomedics | 16.48B |
| Inventage Lab | 3.16B |
| IntoCell | 2.47B |
| AprilBio | 725.35M |